[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalised-lipodystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalised-lipodystrophy":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100234123",false,"NCT02325674","MEASuRE: Metreleptin Effectiveness And Safety Registry","MEASuRE","Inclusion Criteria:\n\n* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry\n* Patients who provide a written consent\n* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply\n\nExclusion Criteria:\n\n• Patients currently treated with an investigational agent as part of a clinical trial","ALL",{"count":17,"type":18},100,"ESTIMATED","10 Years","OBSERVATIONAL","The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.",[23,24],"Generalised Lipodystrophy","Partial Lipodystrophy",[26,27],"Lipodystrophy","Metreleptin Registry","RECRUITING","2026-01-16",{"date":31,"type":32},"2026-01-20","ACTUAL",{"date":34,"type":32},"2016-10-11",{"date":36,"type":18},"2031-10-31",{"name":38,"class":39},"Amryt Pharma","INDUSTRY",28,""]